Sponsored Content: Press releases may be published as paid or sponsored content. The issuers of these press releases are solely responsible for their content. BioInformant is not responsible for the accuracy or claims made in these announcements and does not endorse the views expressed by their issuers.
TriHaz Solutions Opens New Nashville, Tennessee Facility to Expand Regulated Medical Waste Services Across Tennessee
Nashville, TN – July 16, 2025 – TriHaz Solutions, a trusted provider of regulated medical waste management, is proud to announce the opening of a new operational facility in Nashville, Tennesee. This expansion strengthens TriHaz’s ability to serve healthcare facilities, laboratories, and clinical operations throughout Tennessee with reliable and fully compliant medical waste disposal services. [Read more…]
Incucyte® CX3 System transforms continuous analysis of 3D cell models with confocal imaging and unmatched throughput
-
New confocal fluorescence imaging minimizes photobleaching and phototoxicity effects, capturing clear images of live 3D culture
-
Industry-leading throughput enables real-time analysis of up to six microplates in parallel, maximizing data generation
-
Comprehensive, intuitive workflows with integrated data analysis empower every scientist to generate high-quality data from complex assays with greater speed and confidence
Longeveron® Announces Licensing of New Cardiac Selective iPSC Technology for Cardiovascular Disease
-
Longeveron has licensed issued US Patent 12,168,028 B2, entitled “Methods for obtaining cardiomyogenic precursor cells” from the University of Miami
-
New patent protects a method to derive GHRH-Receptor+ cardiomyogenic cells from pluripotent stem cells (PSCs)
-
New technology substantially advances Longeveron’s repertoire of stem cell therapy technologies
-
Opportunity to expand pipeline in cardiovascular, rare and pediatric disease areas
First-in-Human Trial of OpCT-001: An iPSC-Derived Cell Therapy for Primary Photoreceptor Diseases
-
OpCT-001 is the first iPSC-derived investigational cell therapy to be clinically tested for treating primary photoreceptor diseases
-
Phase 1/2a trial, CLARICO, is a first-in-human, multisite, 2-part interventional trial to evaluate the safety, tolerability, and the effect on clinical outcomes of OpCT-001
-
Primary photoreceptor diseases are a subgroup of inherited retinal disorders that affect the structure and function of the photoreceptor cells in the retina, leading to irreversible vision loss in children and adults
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 118
- Next Page »